Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Evaxion Biotech AS
EVAXCurrent price
1.65 USD
+0.06 USD (+3.77%)
Last closed
1.49 USD
Company
www.evaxion-biotech.com
ISIN
US29970R3030
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
10 043 347 USD
Yield for 12 month
-92.31 %
1Y
3Y
5Y
10Y
15Y
EVAX
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark. Address: Dr. Neergaards Vej, Horsholm, Denmark, 2970
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
13.25 USDP/E ratio
–Dividend Yield
–Current Year
+3 344 000 USD
Last Year
+73 000 USD
Current Quarter
+122 000 USD
Last Quarter
+122 000 USD
Current Year
+3 344 000 USD
Last Year
+72 888 USD
Current Quarter
+122 000 USD
Last Quarter
–
Key Figures EVAX
1 year
3 years
5 years
10 years
EBITDA
-14 369 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-72.57 %
PEG Ratio
–
Return On Equity TTM
-802.80 %
Wall Street Target Price
13.25 USD
Revenue TTM
3 344 000 USD
Book Value
-1.18 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
67.10 %
Dividend Yield
–
Gross Profit TTM
3 344 000 USD
Earnings per share
-10.00 USD
Diluted Eps TTM
-10.00 USD
Most Recent Quarter
I 2025
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics EVAX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History EVAX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:5
Payout Ratio TTM
–
Last Split Date
14.01.2025
Stock Valuation EVAX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
3.57
Enterprise Value Revenue
4.51
Price Sales TTM
3.00
Enterprise Value EBITDA
-0.59
Price Book MRQ
14.02
Financials EVAX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators EVAX
For 52 weeks
1.20 USD
21.55 USD
50 Day MA
1.84 USD
Shares Short Prior Month
22 395
200 Day MA
8.53 USD
Short Ratio
0.55
Shares Short
41 825
Short Percent
0.88 %
BeatStart